The dangerous anti-abortion victory buried in Trump's megabill
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
New turnpike director outlines goals for Maine's 'economic backbone'
Jul. 7—When Andre Briere became executive director of the Maine Turnpike Authority in April, he knew he was hired to fix it. After three months on the job, he's got a long to-do list and a two-year action plan that kicks off in August. It will focus on improving the 109-mile toll highway as "the main thing," he says, and avoid distractions from the authority's core mission, like the controversial Gorham Connector proposal that put the agency "through the wringer" last year. The list includes reviving transparency and trust in the authority, increasing digital technology, security and automation at toll plazas and improving service plazas with updated bathrooms, children's play areas and new dining options, which could include Chick-fil-A, Shake Shack and local chefs that would highlight Maine's farm-to-table restaurant scene. Getting rid of the turnpike authority — something opponents have espoused lately and the goal of several failed bills in the last legislative session — isn't on Briere's list for all the reasons he says the agency benefits the state and its residents. That includes where most of the $170 million in tolls, or 89% of the agency's revenue for a $192 million budget, came from last year. "Almost two-thirds of our toll revenue comes from out-of-staters," Briere said. "There's no cheaper way for Mainers to run the economic backbone of the state. It would be financially ruinous for the state of Maine if you changed that." Briere, 57, started at the authority one month after the board of directors dumped the Gorham Connector proposal, leaving it to the Maine Department of Transportation to solve commuter congestion west of Portland. The four-lane toll road would have run from the recently rebuilt turnpike Exit 45 in South Portland, through Westbrook and Scarborough, to the Gorham Bypass at Route 114 in Gorham. A survey conducted by the authority showed the tide of public opinion had ebbed against the connector and the agency itself after spending more than 20 years and $18 million planning and developing the $331 million project. Briere describes the connector proposal as a well-intentioned effort that the authority took on because the Department of Transportation couldn't afford it. While the authority maintains just 577 lane miles of Interstate 95 from Kittery to Augusta, the department looks after 47,248 lane miles of roads across the state. "The DOT struggles to find funding to do projects," he said. "They turned to the turnpike authority to do the connector project and our existence was threatened in the Legislature as a result." It's a misfire Briere doesn't intend to repeat. He's committed to bolstering confidence and trust in the authority and emphasizing transparency and openness with the public, he said. He also wants to make sure the authority's 400 employees are empowered to do their best work after a report last year found that a climate of intimidation and favoritism had been fostered by former chief financial officer Doug Davidson, who left the agency in 2023. "You have to really listen to people, even opponents, and take in their input," he said. "I'm here to serve the people of Maine and make sure the turnpike is the most efficient, modern and innovative highway of its kind in the country." SEPARATE BUT WORKING TOGETHER Briere replaced Peter Mills, the longtime executive director who led the connector project before retiring in September. He took the reins as opponents of the 5-mile toll spur pitched legislation aimed taking control of the authority's spending and project planning powers and folding the agency into the Department of Transportation — something that's been tried unsuccessfully more than 25 times in the past. That's a bad idea, according to Briere, whose last job was deputy commissioner of the New Hampshire Department of Transportation, which operates a turnpike system stretching over 90 miles. Because New Hampshire's three turnpikes are funded by legislators through the state budget, Briere said the process of raising tolls and allocating revenue for highway projects is politicized, and elected officials do what they can to avoid upsetting taxpayers. Last spring, Republican Gov. Kelly Ayotte dismissed senators' calls to increase tolls for the first time in 15 years. As a result, "there's no money for capital spending in New Hampshire's turnpike budget for the coming year," Briere said. Without regular reinvestment in turnpike infrastructure — bridges, toll plazas, air conditioners — the viability of the system diminishes, Briere said, and if tolls don't cover turnpike needs, the system becomes increasingly dependent on taxes. That kind of uncertainty can lower a state's bond rating and increase the cost of borrowing, he said. The Maine Turnpike Authority is somewhat insulated from that process because it's a separate state agency created by the Legislature in 1941 to finance and build the turnpike through toll collection. When the initial bonds were paid off in 1982, the Legislature decided the authority should continue to operate and maintain the turnpike. While no federal or state tax dollars have ever been used on the turnpike, the authority has paid the Maine Department of Transportation $5.4 million to $9.5 million annually since 2011 for work on cooperative projects. They include the $42 million Saco interchange set to open this year, the Sarah Mildred Long and Piscataqua River bridge projects, and planned investments in public transit initiatives in Greater Portland. Briere said he's an advocate for public transit, but he believes it can only be successful if roads aren't mired in commuter gridlock. And he believes it's impossible to stop people from moving outside metropolitan areas, especially as developers continue to build housing and real estate values continue to rise. The authority's contribution the Department of Transportation represented at least 5% of turnpike toll revenue each year, Briere said, and he'll be looking for ways to increase collaboration on projects in the future. "We're better off being separate but working together," he said. BALANCING EFFECTIVENESS AND EFFICIENCY A Seattle native with New England roots, Briere is a 29-year Air Force veteran who retired as a colonel in 2019 with a breadth of international experience in transportation, logistics, emergency management and large-scale project leadership. He is married with two adult children. He admits his military experience likely will help fulfill his action plan for the authority, including digital upgrades in the wake of an E-ZPass shutdown for 12 hours in March that avoided a security breach. The plan calls for providing much smaller E-ZPass sticker tags instead of the current transponders within a year; offering a Maine Turnpike app so E-ZPass users can manage accounts more easily online within two years; and making it possible for drivers to pay tolls with credit cards. "We'll also operate with the general philosophy of keeping tolls low or flat for Maine E-ZPass users," Briere said, noting that those drivers received nearly $11 million in toll discounts in 2024. With the move toward greater automation, the authority may see a further reduction in toll plaza staffing, which has fallen from nearly 400 to about 175 in the last 20 years. However, given the problems that other turnpike systems have experienced when electronic toll systems go offline, Briere said he doesn't see a time when the Maine Turnpike is fully automated. "There's always a balance between effectiveness and efficiency," he said. Copy the Story Link
Yahoo
9 minutes ago
- Yahoo
Better Growth Buy: Eli Lilly vs. Viking Therapeutics
Eli Lilly is a leader in the weight loss drug market, generating blockbuster revenue. Viking Therapeutics recently launched a phase 3 trial for its weight loss candidate -- and could have a promising future in the market. 10 stocks we like better than Eli Lilly › Though you may think "tech stocks" when someone mentions growth, you actually can find growth stocks throughout a wide variety of industries. Even those like pharmaceuticals, often known for the steadiness of their earnings, may, through certain specialty areas, offer you the opportunity for explosive growth. And today, the perfect example is weight loss drugs. Today's $28 billion weight loss drug market is on track to reach nearly $100 billion by 2030, according to Goldman Sachs Research, offering companies in the space an extremely solid opportunity over the next several years and likely beyond. Two names that have been making headlines in this field are Eli Lilly (NYSE: LLY) and Viking Therapeutics (NASDAQ: VKTX). The former is a current leader, already selling two blockbuster drugs prescribed for weight loss, and the latter is an up-and-coming player, with a candidate in late-stage trials. Which is the better growth buy today? Let's find out. Eli Lilly shares weight loss drug market leadership with fellow big pharma player Novo Nordisk. They each commercialize two drugs prescribed to people aiming to lose weight and have brought in billions of dollars in annual revenue. Here, I'll focus on Lilly. The company's drugs, Mounjaro and Zepbound, are actually the same compound, tirzepatide. But it's sold under the name Mounjaro for type 2 diabetes and under the name Zepbound for weight loss. The drug acts by stimulating hormonal pathways involved in the control of blood sugar levels and appetite. Thanks to the efficacy of tirzepatide, demand has soared, even surpassing supply until Lilly expanded its production capacity. But Lilly isn't sitting still in the area of weight loss. The company also is developing other drug candidates that may improve upon tirzepatide. The closest to market right now is orforglipron, Lilly's oral candidate for weight loss that recently delivered positive phase 3 trial results. If approved, it would be the only oral weight loss drug of its class that doesn't require strict food and water restrictions. Lilly aims on applying for regulatory review by the end of this year. All of this could result in more growth for Lilly this year and well into the future. Viking Therapeutics is a biotech company specializing in metabolic conditions, and it's made great progress with its obesity drug candidate, VK2735. The potential drug, in subcutaneous form, recently entered a phase 3 trial, and an oral form is involved in a phase 2 trial. These candidates are in the same class as tirzepatide, so work in the same way. Investors have shown their excitement about Viking's program in the past: When the company reported positive phase 2 data for the subcutaneous VK2735 last year, the stock soared more than 120% in one trading session. The stock hasn't maintained those gains, but the movement shows that investors are interested in the program -- and more good news ahead could boost the stock again. Now you might wonder why investors are so excited about Viking if there already are other successful weight loss drugs on the market -- and Lilly even is likely to reach commercialization with an oral weight loss drug ahead of Viking. This is because demand is high, and this is set to continue, so there is plenty of room for more than a couple of companies to succeed in the space. Investors also have speculated about the idea of a big pharma company acquiring Viking to get in on this high growth market. Lilly has the first-to-market advantage, is closer to the finish line with an oral candidate, and already is generating major revenue from its weight loss portfolio. Viking, if successful through clinical trials, could carve out market share and deliver major revenue growth down the road -- or the company could be acquired, offering investors another way to potentially gain. Each company offers certain advantages. Now let's answer our question. If all goes well for Viking, it could represent the better growth buy as, starting from zero product revenue today, this player could see revenue soar if and when it brings a weight loss drug to market. And we've seen that Viking's stock price is very reactive to news, meaning the stock could skyrocket in such a scenario. But, if you go the Viking route, you should be comfortable with risk as uncertainty remains: The company hasn't yet reached the finish line with a product. If you're more of a cautious investor, though, don't worry. You may opt for Lilly as, even though it's climbed 140% over the past three years, it still could have plenty of room to run over the long term thanks to this weight loss drug growth story. Before you buy stock in Eli Lilly, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Eli Lilly wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $699,558!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $976,677!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 30, 2025 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Goldman Sachs Group. The Motley Fool recommends Novo Nordisk and Viking Therapeutics. The Motley Fool has a disclosure policy. Better Growth Buy: Eli Lilly vs. Viking Therapeutics was originally published by The Motley Fool
Yahoo
9 minutes ago
- Yahoo
3 Cash-Heavy Stocks Worth Investigating
A clean balance sheet can signal disciplined management and stability. It also means a company can expand and thrive without relying on borrowed capital. Not all companies with sound capital structures are created equal, and StockStory is here to help you find the best. Keeping that in mind, here are three companies with net cash positions that can continue growing sustainably. Net Cash Position: $76.13 million (4.4% of Market Cap) Founded in 1987, American Superconductor (NASDAQ:AMSC) has shifted from superconductor research to developing power systems, adapting to changing energy grid needs and naval technology requirements. Why Are We Bullish on AMSC? Impressive 45% annual revenue growth over the last two years indicates it's winning market share this cycle Free cash flow margin is now positive, showing the company is at an important crossroads Improving returns on capital suggest its past investments are beginning to deliver value American Superconductor's stock price of $39.39 implies a valuation ratio of 75.2x forward P/E. Is now the time to initiate a position? Find out in our full research report, it's free. Net Cash Position: $259.3 million (2.4% of Market Cap) Originally launched with a focus on stigmatized conditions like hair loss and sexual health, Hims & Hers Health (NYSE:HIMS) operates a consumer-focused telehealth platform that connects patients with healthcare providers for prescriptions and wellness products. Why Is HIMS a Good Business? Average customer growth of 48.6% over the past two years demonstrates success in acquiring new clients that could increase their spending in the future Earnings per share have massively outperformed its peers over the last four years, increasing by 37% annually Free cash flow margin grew by 23.5 percentage points over the last five years, giving the company more chips to play with At $47.98 per share, Hims & Hers Health trades at 36.3x forward EV-to-EBITDA. Is now the right time to buy? See for yourself in our full research report, it's free. Net Cash Position: $299.7 million (9.4% of Market Cap) Founded in 2013 as a champion for content creator rights and free expression, Rumble (NASDAQ:RUM) is a video sharing platform that positions itself as a free speech alternative to mainstream platforms, offering creators more favorable revenue-sharing opportunities. Why Could RUM Be a Winner? Impressive 38.4% annual revenue growth over the last two years indicates it's winning market share this cycle Rumble is trading at $9.35 per share, or 21.9x trailing 12-month price-to-sales. Is now a good time to buy? Find out in our full research report, it's free. Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
